Comparison of Analgesic Requirements in Patients Receiving Nuss Operation Using 2 Different Anesthetic Adjuvants (ARNRD)
18 mars 2020 mis à jour par: Jung Min Koo
Comparing Analgesic Requirements in Patients Receiving Nuss Operation Using Remifentanil or Dexmedetomidine as Anesthetic Adjuvants
Nowadays, general anaesthesia is carried under "balanced anesthesia technique" in which many anesthetic adjuvants are used simultaneously, including opioid analgesics in order to reduce the amount of inhalation agents. The most popular adjuvants used are remifentanil, which is an opioid analgesic, and dexmedetomidine. Both of these agents are short acting, can be infused with targeted concentrations, excreted shortly from the body with stable hemodynamics.
Remifentanil, when infused for more than 2 hours, causes hyperalgesia to increase the amount of pain postoperatively as well as the amount of opioid analgesics. However, dexmedetomidine does not cause hyperalgesia and is known to have an opioid -sparing effect. In our center.
In this study, we aim to compare the effects of remifentanil and dexmedetomidine on postoperative pain in patients undergoing Nuss procedure, which is a very painful operation on the chest wall.
Aperçu de l'étude
Statut
Inconnue
Les conditions
Intervention / Traitement
Type d'étude
Interventionnel
Inscription (Anticipé)
62
Phase
- N'est pas applicable
Contacts et emplacements
Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.
Lieux d'étude
-
-
-
Seoul, Corée, République de
- Jung Min Koo
-
-
Critères de participation
Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.
Critère d'éligibilité
Âges éligibles pour étudier
20 ans à 60 ans (Adulte)
Accepte les volontaires sains
Non
Sexes éligibles pour l'étude
Tout
La description
Inclusion Criteria:
- Adults aged >20
- Patients undergoing Nuss bar operation (pectus excavatum repair surgery)
- American Society of Anesthesiologists classification I ~ III
Exclusion Criteria:
- Drug abuse history
- Chronic pain in need of continuous opioid analgesics administration
- History of psychiatric diseases
- Preoperative bradycardia (heart rate < 50/min) or arrythmia
- Cardiac diseases other than diabetes or hypertension - coronary artery disease, ischemic heart disease
- Moderate liver or kidney dysfunction
- Pregnant or breast feeding women
- Hypersensitivity to the study drugs
- Patients who do not agree to participate
Plan d'étude
Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Tripler
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Comparateur factice: Remifentanil group
In both interventional groups, Sevoflurane is used as an inhalational agent, in 0.5-1.5% age-adjusted Minimal Alveolar Concentration (MAC).
As explained above, remifentanil is infused with Target Controlled Infusion pump, and concentration is adjusted so that Bispectral index (BIS) is maintained as 40-60, which means that the patients are maintained in general anesthesia.
Remifentanil is usually infused with the effect site concentration of 2.0 to 6.0 ng/ml during general anesthesia.
If bradycardia or hypotension develops due to remifentanil infusion, the infusion rate could be reduced, or inotropic, vasopressor, anticholinergic agents can be used (ephedrine, atropine, etc.) to correct the side effects of the drug, or the drug infusion can even be ceased.
At the end of the surgery when skin closure starts, remifentanil infusion will be stopped.
|
Comparing effects of remifentanil versus dexmedetomidine
Autres noms:
|
|
Comparateur actif: Dexmedetomidine group
In both interventional groups, Sevoflurane is used as an inhalational agent, in 0.5-1.5% age-adjusted MAC (Minimal Alveolar Concentration).
As explained above, dexmedetomidine is infused with syringe pump, and concentration is adjusted so that Bispectral index (BIS) is maintained as 40-60, which means that the patients are maintained in general anesthesia.
Dexmedetomidine is loaded for 10 minutes in 1mcg/kg, and then infusion rate is set between 0.4 to 0.6mcg/kg/hour for this study.
If bradycardia or hypotension develops due to remifentanil infusion, the infusion rate could be reduced, or inotropic, vasopressor, anticholinergic agents can be used (ephedrine, atropine, etc.) to correct the side effects of the drug, or the drug infusion can even be ceased.
At the end of the surgery when skin closure starts, dexmedetomidine infusion will be stopped.
|
Comparing effects of remifentanil versus dexmedetomidine
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Visual Analogue Scale
Délai: Between 1~6 hours postoperatively.
|
Pain scale ranges from 0 to 10. 0 means no pain at all, and 10 being the most severe pain anyone can imagine.
|
Between 1~6 hours postoperatively.
|
|
Visual Analogue Scale
Délai: Between 6~12 hours postoperatively.
|
Pain scale ranges from 0 to 10. 0 means no pain at all, and 10 being the most severe pain anyone can imagine.
|
Between 6~12 hours postoperatively.
|
|
Visual Analogue Scale
Délai: Between 12~24 hours postoperatively.
|
Pain scale ranges from 0 to 10. 0 means no pain at all, and 10 being the most severe pain anyone can imagine.
|
Between 12~24 hours postoperatively.
|
|
Visual Analogue Scale
Délai: Between 24~48 hours postoperatively.
|
Pain scale ranges from 0 to 10. 0 means no pain at all, and 10 being the most severe pain anyone can imagine.
|
Between 24~48 hours postoperatively.
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Amount of postoperative intravenous patient controlled analgesics (PCA) used
Délai: At 60 minutes after the end of surgery
|
At 60 minutes after the end of surgery
|
|
|
Amount of fentanyl used postoperatively at the recovery unit
Délai: At 60 minutes after the end of surgery
|
Amount in micgrograms per wegith in kilograms (migrogram/kilogram)
|
At 60 minutes after the end of surgery
|
|
Time needed for postoperative rescue opioid analgesics
Délai: At 60 minutes after the end of surgery
|
At 60 minutes after the end of surgery
|
|
|
Amount of remifentanil or dexmedetomidine used intraoperatively
Délai: Immediately at the end of the surgery
|
Immediately at the end of the surgery
|
|
|
Intraoperative hemodynamic change: Systolic blood pressure
Délai: 1 minute after monitoring (of blood pressure, heart rate, pulse oxymeter and electrocardiogram) starts, when the patient arrives at the operating room
|
1 minute after monitoring (of blood pressure, heart rate, pulse oxymeter and electrocardiogram) starts, when the patient arrives at the operating room
|
|
|
Intraoperative hemodynamic change: Diastolic blood pressure
Délai: 1 minute after monitoring (of blood pressure, heart rate, pulse oxymeter and electrocardiogram) starts, when the patient arrives at the operating room
|
1 minute after monitoring (of blood pressure, heart rate, pulse oxymeter and electrocardiogram) starts, when the patient arrives at the operating room
|
|
|
Intraoperative hemodynamic change: mean blood pressure
Délai: 1 minute after monitoring (of blood pressure, heart rate, pulse oxymeter and electrocardiogram) starts, when the patient arrives at the operating room
|
1 minute after monitoring (of blood pressure, heart rate, pulse oxymeter and electrocardiogram) starts, when the patient arrives at the operating room
|
|
|
Intraoperative hemodynamic change: heart rate
Délai: 30 minutes after the induction of anesthesia
|
30 minutes after the induction of anesthesia
|
|
|
Intraoperative hemodynamic change: mean blood pressure
Délai: At the end of the surgery, average of 90minutes after the induction of anesthesia
|
At the end of the surgery, average of 90minutes after the induction of anesthesia
|
|
|
Intraoperative hemodynamic change: heart rate
Délai: At the end of the surgery, average of 90minutes after the induction of anesthesia
|
At the end of the surgery, average of 90minutes after the induction of anesthesia
|
|
|
Intraoperative hemodynamic change: Systolic blood pressure
Délai: At the end of the surgery, average of 90minutes after the induction of anesthesia
|
At the end of the surgery, average of 90minutes after the induction of anesthesia
|
|
|
Intraoperative hemodynamic change: Diastolic blood pressure
Délai: At the end of the surgery, average of 90minutes after the induction of anesthesia
|
At the end of the surgery, average of 90minutes after the induction of anesthesia
|
|
|
Rescue drugs (inotropics or vasopressors) used in order to correct hypotension or bradycardia
Délai: Intraoperatively
|
Intraoperatively
|
|
|
Postoperative complications
Délai: Between 1~6 hours postoperatively
|
Number of events that happened to the patient: e.g.
Yes or No, and how many times.
Nausea/vomiting, hypotension, respiratory depression, urinary retension, dizziness, transient cease in use of intravenous patient controlled analgesics (PCA)
|
Between 1~6 hours postoperatively
|
|
Postoperative complications
Délai: Between 12~24 hours postoperatively
|
Number of events that happened to the patient: e.g.
Yes or No, and how many times.
Nausea/vomiting, hypotension, respiratory depression, urinary retension, dizziness, transient cease in use of intravenous patient controlled analgesics (PCA)
|
Between 12~24 hours postoperatively
|
|
Postoperative complications
Délai: Between 24~48 hours postoperatively
|
Number of events that happened to the patient: e.g.
Yes or No, and how many times.
Nausea/vomiting, hypotension, respiratory depression, urinary retension, dizziness, transient cease in use of intravenous patient controlled analgesics (PCA)
|
Between 24~48 hours postoperatively
|
Collaborateurs et enquêteurs
C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.
Parrainer
Les enquêteurs
- Chercheur principal: Jung Min Koo, M.D, Data recruitment
Dates d'enregistrement des études
Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.
Dates principales de l'étude
Début de l'étude (Réel)
2 septembre 2019
Achèvement primaire (Anticipé)
21 février 2021
Achèvement de l'étude (Anticipé)
28 février 2021
Dates d'inscription aux études
Première soumission
20 août 2019
Première soumission répondant aux critères de contrôle qualité
27 août 2019
Première publication (Réel)
29 août 2019
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
20 mars 2020
Dernière mise à jour soumise répondant aux critères de contrôle qualité
18 mars 2020
Dernière vérification
1 mars 2020
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Effets physiologiques des médicaments
- Agents adrénergiques
- Agents neurotransmetteurs
- Mécanismes moléculaires de l'action pharmacologique
- Dépresseurs du système nerveux central
- Agents du système nerveux périphérique
- Analgésiques
- Agents du système sensoriel
- Analgésiques, non narcotiques
- Agonistes des récepteurs adrénergiques alpha-2
- Alpha-agonistes adrénergiques
- Agonistes adrénergiques
- Analgésiques, Opioïdes
- Stupéfiants
- Hypnotiques et sédatifs
- Rémifentanil
- Dexmédétomidine
Autres numéros d'identification d'étude
- KC19MCSI0334
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
NON
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Non
Étudie un produit d'appareil réglementé par la FDA américaine
Non
produit fabriqué et exporté des États-Unis.
Non
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .